Roche Holding AG

“Roche is a rare integrated pharma-diagnostics franchise — the only one of its kind at scale — with fortress finances (ROIC ~17-19%, net leverage ~0.5x EBITDA), a recovering new-product cycle led by Vabysmo, Ocrevus, and Hemlibra, and free optionality from an obesity pipeline that the market has not fully valued. The business is exceptional and the risk of permanent capital impairment is low; however, at 14.8x forward earnings and CHF 322 per share, the margin of safety is thin, the biosimilar recovery is already well-understood by the market, and mid-cycle pipeline setbacks (particularly Ocrevus biosimilar exposure from 2027–2028 onward) could produce sideways drift. The stock is worth owning — but at a price that offers more cushion than it does today.”